Full-Time
Posted on 2/27/2025
Develops therapies for serious genetic diseases
No salary listed
Company Does Not Provide H1B Sponsorship
Boston, MA, USA
In Person
3 days a week on-site in Boston, MA.
MD
See people who can refer or advise you
Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1989
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
Vertex Pharmaceuticals' stock has climbed 15.4% in a month, buoyed by strong second-quarter results and an improved outlook. The company reported revenues of $3.33 billion, up 12% year over year, and raised its full-year guidance to $13.1–$13.2 billion. Vertex's cystic fibrosis (CF) products generated $6.1 billion in the first half of 2026, growing 8.4% year over year. Its newest CF medicine, Alyftrek, performed particularly well, with second-quarter sales of $573.6 million, up 35% sequentially. The drug surpassed $1 billion in cumulative global revenues in the first half of the year. Vertex holds a leadership position in CF, treating nearly 95% of patients in core markets, with no near-term competitive threats. Label expansions and launches in new geographies are expected to drive continued growth.
Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]
Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue of $3.33 billion beating analyst estimates of $3.19 billion. The company attributed growth to its cystic fibrosis portfolio and newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani highlighted that ALYFTREK and TRIKAFTA continued to drive CF revenue, whilst European launches benefitted from fewer monitoring requirements. The company raised its full-year revenue guidance to $13.15 billion at the midpoint from $13.03 billion. Adjusted earnings per share came in at $4.73, in line with analyst expectations of $4.75. Adjusted operating income reached $1.42 billion, exceeding estimates of $1.37 billion with a 42.7% margin. During the earnings call, analysts questioned management about Phase II/III study doses, payer dynamics for JOURNAVX, and clinical outcomes for next-generation CF therapies.
Vertex Pharmaceuticals reported strong second quarter 2026 results during its earnings call on 3 August. The company's total revenue grew 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. CEO Dr Reshma Kewalramani highlighted excellent performance across the company's commercial portfolio and research pipeline. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals, which will add rare endocrine diseases as a fifth therapeutic area alongside cystic fibrosis, sickle cell disease, beta-thalassemia, and pain management. The company emphasised 2026 as a year focused on execution across commercial, clinical, and regulatory fronts, with significant progress made during the quarter.